CD274 and neoplasm: Triple combination treatment of CDDP plus CBP501 and anti-PD-1 (Figure 3I) or anti-PD-L1 (Figure 4I) significantly (P = 0.0045 and P = 0.0078, respectively) enhanced the antitumor effect compared to double combination treatment of CDDP and immune checkpoint inhibitors, and the tumor eradication was confirmed in some mice (Figures 3I and 4I).